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Abstract
The deleted in colorectal carcinoma (DCC ) gene is a
potential tumor-suppressor gene on chromosome
18q21.3. The relatively high frequency of loss of
heterozygosity (LOH) and loss of expression of this
gene in neuroblastoma, especially in the advanced
stages, imply the possibility of involvement of the DCC
gene in progression of neuroblastoma. However, only
few typical mutations have been identified in this gene,
indicating that other possible mechanisms for the
inactivation of this gene may exist. A polymorphic
change (Arg to Gly) at DCC codon 201 is related to
advanced colorectal carcinoma and increases in the
tumors with absent DCC protein expression. In order
to understand whether this change is associated with
the development or progression of neuroblastoma, we
investigated codon 201 polymorphism of the DCC
gene in 102 primary neuroblastomas by polymerase
chain reaction single-strand conformation polymor-
phism. We found no missense or nonsense mutations,
but a polymorphic change from CGA (Arg) to GGA
(Gly) at codon 201 resulting in three types of poly-
morphism: codon 201Gly type, codon 201Arg /Gly type,
and codon 201Arg type. The codon 201Gly type
occurred more frequently in disseminated (stages IV
and IVs) neuroblastomas (72%) than in localized
(stages I, II, and III ) tumors (48%) (P=.035), and
normal controls (38%) (P=.024). In addition, the
codon 201Gly type was significantly more common in
tumors found clinically (65%) than in those found by
mass screening (35%) (P=.002). The results sug-
gested that the codon 201Gly type of the DCC gene
might be associated with a higher risk of disseminat-
ing neuroblastoma. Neoplasia (2001) 3, 267–272.
Keywords: tumor - suppressor gene, the DCC gene, PCR -SSCP, codon 201 polymorph-
ism, neuroblastoma.
Introduction
Inactivation of the tumor-suppressor gene has been shown
to play an important role in the development of a variety of
human cancers [1 ]. The deleted in colorectal carcinoma
(DCC ) gene, initially identified as a candidate tumor-
suppressor gene on chromosome 18q21.3 in colorectal
carcinoma [2], shows frequent allelic deletion and aberrant
expression in many human tumors [3,4 ]. Alterations of the
DCC gene are also associated with metastasis of various
carcinomas [5–11]. The DCC gene encodes a neural cell
adhesion molecule (NCAM)- like transmembrane protein. Its
extracellular domain has four immunoglobulin ( Ig) - like and
six fibronectin type III - like domains, which have high
homology to frazzled and UNC-40, the two transmembrane
proteins of the Ig superfamily that are mainly expressed on
motor neurons of the nervous system [12,13]. The cytoplas-
mic domain of the DCC gene shares similarity to neogenin.
The expression of neogenin is dynamically regulated in the
developing nervous systemof chickens [14]. In addition, DCC
has been identified as a receptor for netrin-1, a molecule
involved in axon guidance and cell migration during develop-
ment [15]. Thus, the DCC gene is a critical gene in regulating
the growth and differentiation of the neural -origin cells.
Although there is no increase in the frequency of tumor
formation in DCC hemizygous mice [16], reestablishment of
the expression of DCC suppresses tumorigenicity [17,18].
Furthermore, DCC can induce apoptosis in cells outside the
region of ligand availability (e.g., metastatic cells or locally
invasive cells ), suggesting that DCC may function as a
tumor-suppressor and play a major role in suppressing
invasion or metastasis of tumor cells [19].
Neuroblastoma is a malignant tumor of neural crest origin.
It is very common in childhood neoplasm with an incidence of
about 1 in 100,000 to 130,000 children under 15 years of age
[20]. We have reported the relatively high frequency of loss of
heterozygosity (LOH) (31%) at DCC locus on chromosome
18q21 in neuroblastoma [21]. Reduced ormissing expression
of the DCC gene at the mRNA and protein levels in advanced
stages of neuroblastoma has been observed both by us and
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by other groups [22–24], indicating that DCC is probably
involved in the tumorigenesis of neuroblastoma. However,
only a few mutations have been identified in this gene [23].
It is thus possible that mechanisms other than mutations
are responsible for the inactivation of this gene. A
polymorphic change (Arg to Gly) at DCC codon 201 was
found to be related to advanced colorectal carcinomas and
carcinomas lacking DCC protein expression [25,26]. In our
previous study, this polymorphic change was observed in
varieties of neuroblastoma cell lines and primary tumors
[23]. Thus, we hypothesize that this polymorphic change
might be associated with the development or progression
of the neuroblastoma in the same way as it is in the
colorectal carcinoma. In order to test this hypothesis, we
investigated codon 201 polymorphism of the DCC gene in
102 primary tumors by polymerase chain reaction single-
strand conformation polymorphism (PCR-SSCP), followed
by sequencing.
Materials and Methods
Primary Tumor Specimens
One hundred and two tumor specimens were obtained
from neuroblastoma patients. The samples were taken from
the patients either at Saitama Children’s Medical Center or at
the University of Tokyo Hospital before chemotherapy.
Tissue specimens were immediately frozen in liquid nitrogen
after the surgical removal and stored at 808C. Twelve
noncancerous tissues including peripheral blood bone
marrow were obtained from some of the above patients of
stages I and II. The informed consent was obtained from the
parents of the patients before the samples were taken.
Twenty-one peripheral blood samples as normal controls for
PCR-SSCP were obtained from healthy volunteers.
Patient Data
The stages of neuroblastoma were defined according to
the classification of Evans et al. [27]. One hundred and two
patients, aged from 18 days to 16 years with a median age of
12 months, were examined. These included 68 males and 34
females. Twenty- three were classified as stage I, 27 stage II,
16 stage III, 32 stage IV, and 4 stage IVs. Twenty-six
patients including 13 stage I, 12 stage II, and 1 stage III were
found bymass screening [28]. The status of theN-myc gene
was examined in 59 patients including 12 patients in stage
IV, five of whom had amplification. Patients in stages I and II
were treated by either surgery alone or surgery plus
chemotherapy that mainly consisted of vincristine and
cyclophosphamide without radiotherapy. Patients in stages
III and IV were administered with multidrug chemotherapy
consisting of cyclophosphamide, doxorubicin, cisplatinum,
and etoposide with or without surgery, radiotherapy, and
hematopoietic stem cell transplantation [29].
PCR-SSCP Analysis of DCC Mutations
High-molecular -weight DNA was prepared from tumor
tissues using the proteinase-K phenol–chloroform method
and PCR-SSCP was performed as previously described
[23]. The oligonucleotide primers for amplifying DCC codon
201 span a 353- fragment and were synthesized as
described by Miyake et al. [5 ]. PCR for genomic DNA
amplification proceeded in a 5-ml mixture containing 50 mM
KCl, 10 mM Tris–HCl (pH 8.3), 1.5 mM MgCl2, 100 mM of
each dNTP, 5 pmol of each primer, 2.5 ml of [ -32P] dCTP
(3000 Ci /mmol), and 0.25 units of Taq polymerase
(Boehringer Mannheim, Mannheim, Germany). The PCR
consisted of an initial denaturing step: 2 minutes at 948C; 35
cycles of amplification: 1 minute at 948C for denaturation, 1
minute at 568C for annealing, 1 minute at 728C for extension,
and 7 minutes at 728C for the final extension step. After
amplification, PCR mixtures were heated for 5 minutes at
808C with 45 L of formamide denaturing dye mixture (95%
formamide, 20 mM EDTA, 0.05% xylene cyanol, 0.05%
bromophenol blue), and then resolved by electrophoresis on
a 5% nondenaturing polyacrylamide gel containing 45 mM
Tris–borate (pH 8.3), 4 mM EDTA, and 1.6% Amp
(ammonium peroxodisulfate) with and without 10% glycerol.
Electrophoresis proceeded at 40 W for 2 to 3 hours at 268C
or 48C. Gels were dried on filter paper and exposed to X-ray
film at 808C overnight.
Direct Sequencing of PCR-Amplified Fragments
Sequencing was performed as previously described [23].
Small gel slices containing the shift band detected by SSCP
Figure 1. Three types of codon 201 polymorphism within exon 3 of the DCC
gene. Exon 3 was amplified from six primary tumors of neuroblastoma by
PCR-SSCP and subjected to polyacrylamide gel electrophoresis. Three
patterns of the bandshifts were noted on the electrophoresis gel and they are
named as codon 201Arg type, codon 201Gly type, and codon 201Arg / Gly type
according to the sequencing result.
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were excised, immersed in 20 L of water, and placed at
room temperature overnight. The extracts were centrifuged
and PCR-amplified as described above. PCR products were
purified using a Microcon 100 (Amicon, Beverly, MA) and
sequenced by the dideoxy chain termination method.
Results
Using PCR-SSCP methodology, we investigated exon 3 of
the DCC gene for codon 201 polymorphism in the 102
primary tumors, 12 noncancerous tissues, and 21 normal
peripheral blood samples. Three patterns of band distribution
were noted on the SSCP electrophoresis gels (Figure 1 ).
DNA sequencing revealed that the polymorphism resulted
from a CGA (Arg) to GGA (Gly) transversion in codon 201 at
one or both alleles of the DCC gene (Figure 2 ). In tumor
tissues, the most frequent transversion type was codon
201Gly (Figure 2A ), which had one or two homozygous
codon 201Gly alleles. The less frequent type was codon
201Arg /Gly type containing heterozygous codon 201Arg allele
and codon 201Gly allele (Figure 2B ). The least observed
type was codon 201Arg type, which consisted of one or two
homozygous alleles of wild type codon 201Arg (Figure 2C ).
In the 102 primary tumors, the frequencies of the codon
201Gly, codon 201Arg /Gly, and codon 201Arg types were 57%
(58/102), 37% (38/102), and 6% (6/102), respectively.
The types of codon 201 polymorphism were significantly
correlated with the stages of neuroblastoma (P=.047, by
Kruskal -Wallis test ). The frequency of codon 201Gly type in
stage IV+IVs tumors (26/36, 72%) was significantly higher
than that in stage I+II+III tumors (32/66, 48%) (P=.035, by
chi -square analysis) and that in normal controls (8 /21,
38%) (P=.024, by chi -square analysis) (Table 1). Among
the 26 tumors found by mass screening, 9 (35%) were
codon 201Gly type, 12 (46%) were codon 201Arg /Gly, and 5
(19%) were codon 201Arg. In the 76 tumors found clinically,
the frequencies of the three types were 49 (65%), 26 (34%),
and 1 (1%), respectively. Codon 201Gly type of the DCC
Figure 2. Position and nature of the codon 201 polymorphism. Small gel slices from the top second bands shown in Figure 1 were excised and applied to sequencing
after PCR amplification. Variation of sequences at codon 201 was observed: codon 201Gly (A ), a mutation of CGA (Arg ) to GGA (Gly ) at codon 201; codon
201Arg / Gly (B ), both GGA (Gly ) and CGA (Arg ) present at codon 201; codon 201Arg (C ), the wild type CGA (Arg ) at codon 201. Arrow heads indicate the
polymorphism nucleotides.
Table 1. Correlation of Codon 201 Polymorphic Types of the DCC Gene with the Stages of Neuroblastoma.
Stages Number of total samples Number (% ) of codon 201Gly Number (% ) of codon 201Arg / Gly Number (%) of codon 201Arg
I* 23 10 (43%) 11 (48%) 2 (9%)
II* 27 13 (48%) 11 (47%) 3 (11%)
III* 16 9 (56%) 6 (44%) 0
IV 32 23 (72%) 8 (25%) 1 (3%)
IVs 4 3 (75%) 1 (25%) 0
Total 102 58 (57%) 38 (37%) 6 (6%)
Normal control** 21 8 (38%) 10 (48%) 3 (14%)
The codon 201 polymorphic types of the DCC gene were significantly correlated with the stages of neuroblastoma (P= .047, by Kruskal -Wallis test ). The
frequency of codon 201Gly type was significantly higher in stages IV+ IVs (26 /36, 72%) than in stages I, II, and III ( 32 / 66, 48%) ( *P= .035, by chi - square
analysis ) and in normal control ( 8 / 21, 38%) ( **P= .024, by chi - square analysis ).
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gene was significantly more frequent in the tumors found
clinically (65%) than in those found by mass screening
(35%) (P=.002, by chi -square analysis). Of the five tumors
with N-myc amplification, codon 201Gly type was detected in
two, codon 201Arg /Gly type in two, and codon 201Arg type in
one tumor, respectively. The corresponding noncancerous
tissues from stages I and II patients showed the same codon
201 alleles with the tumor tissues.
Discussion
The DCC gene on chromosome 18q21 is considered to be
one of the candidate tumor-suppressor genes in neuro-
blastoma because of the high frequency of LOH at DCC
locus on chromosome 18 [21], the presence of a functional
protein in primary tumors versus loss of expression in
metastatic deposit, and the frequent reduced or loss of
expression in advanced or disseminated tumors [22–24].
However, mechanisms for DCC inactivation are still
unknown because only few mutations have been detected
in neuroblastomas [23].
A polymorphic change from CGA (Arg) to GGA (Gly) at
codon 201 of theDCC gene has been found to be associated
with the progression of the colorectal carcinomas [25,26].
Minami et al. [25] demonstrated that codon 201Gly type was
significantly increased in invasive colorectal carcinomas than
adenomas, and 9 of 10 invasive cancer cases with LOH had
remained only codon 201Gly allele. Another study by Schmitt
et al. showed that 7 of 15 cases of the malignant colorectal
tissues newly changed from codon 201Arg /Gly to codon
201Gly /Gly (both were codon 201Gly alleles) compared with
their corresponding normal mucosa. The results from these
two studies indicate that change from codon 201Arg /Gly to
codon 201Gly type (remaining one codon 201Gly allele due to
LOH [25] or two codon 201Gly alleles due to mutation [26] ) is
related to the malignant transformation. Previously, we found
that the codon 201Gly type is frequently observed in neuro-
blastoma [23]; thus, we proposed that the polymorphic
change from Arg to Gly at codon 201 of the DCC gene might
be associated with neuroblastoma progression. Our results
from the present study demonstrated that the codon 201Gly is
more prevalent in disseminated neuroblastoma (stages IV
and IVs) than in localized tumors (stages I, II, and III ). In
addition, the frequency of this abnormality is significantly
higher in the patients found clinically than in those found by
mass screening. This may be explained by the fact that most
of the patients found by mass screening have stage I or II
tumors. The data from this study suggest that the codon
201Gly type is likely related to a higher risk of dissemination of
tumor cells. However, how codon 201Gly type becomes more
prevalent in disseminated neuroblastoma remains unknown.
Twelve noncancerous tissue specimens from stages I and II
neuroblastomas (nondisseminated tumors) had the same
codon 201 polymorphism types as the tumor tissues in the
present study, indicating that the variation at codon 201 of
the DCC gene is an inherited polymorphism. Thus, the
possible explanations for the high incidence of codon 201Gly
type in the disseminated neuroblastomas might be as
follows. One possibility is that the codon 201Arg allele is
preferentially lost in tumor cells due to LOH or mutation
during progression of neuroblastoma similar to the scenario
that happened in the advanced colorectal carcinoma
[25,26]. The other possibility is that individuals with two
codon 201Gly alleles are more susceptible to disseminated
neuroblastoma than those without the codon 201Gly allele.
We considered that the first mechanism is more possible in
neuroblastoma based on the studies of others [25,26];
however, the second cannot be excluded until we compare
the codon 201 polymorphism between tumors and the
adjacent normal tissues from the patients with disseminated
neuroblastomas in the future.
Not only unique somatic mutations in a gene could
change the protein conformation and reduce or abolish the
function of the gene, many functional polymorphisms intend
to affect the expression of the protein and its activities [30–
33]. The polymorphic change from CGA (Arg) to GGA (Gly)
at codon 201 was also found to be associated with loss of the
DCC protein in colorectal carcinomas [26]. Eight of nine
colorectal tumors with both codon 201Gly alleles had no
detectable DCC expression. Importantly, seven of them
acquired a new codon 201Gly allele through mutation of Arg
to Gly. Although we did not examine the DCC protein
expression due to the limited amount of neuroblastoma
samples, the polymorphic change from Arg to Gly at codon
201 resulting in codon 201Gly type documented in our study
seems to have a good agreement with the loss of protein
expression in neuroblastoma reported by Reale et al. [22].
First, our finding that codon 201Gly type was more prevalent
in the disseminated tumors is consistent with Reale et al.’s
result that loss of DCC protein expression was more
frequently observed from patients with stage IV or IVs
tumors. Second, stage IVs neuroblastomas occur in patients
less than 1 year of age, and the majority of tumors
spontaneously regress despite dissemination to distant sites
[34]. Three of the four tumors from stage IVs patients
showed the codon 201Gly type, implying that this mutation is
probably related only to the higher risk of tumor cell
dissemination, regardless of their true malignant potential.
This result is consistent with the finding that DCC protein
expression was undetectable in most stage IVs tumors [22].
Third, our study found that five neuroblastomas with N-myc
amplification did not show a prediction to any codon 201
polymorphic type, indicating that the polymorphic change at
codon 201 might be involved in the dissemination, not
through the pathway regulated by N-myc. This phenomenon
also agrees with the finding that there is no consistent
relationship between loss of DCC protein and N-myc
amplification [22]. However, because only a small number
of cases in the second and third scenarios were investigated,
further studies involving larger patient populations are
required. In any case, it will be very interesting in the future
to investigate the relationship between loss of DCC protein
expression and codon 201 genotypes in disseminated
neuroblastoma.
The association of the polymorphic change from Arg to
Gly at codon 201 with the tumor progression or dissem-
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ination indicates that codon 201Gly type protein might have a
weaker function than codon 201Arg type protein. Codon 201
is in the second of the four Ig- like domains of the DCC gene.
This domain is in a highly conserved region that shares high
similarity with adhesion molecule NCAM [2]. Developing
neoplasia and metastasis is often associated with disruption
of cell adhesion or cell - to-cell contacts [35,36]. The
polymorphic change at codon 201 is from the amino acid
Arg to Gly. The Arg is a basic, hydrophilic amino acid and has
a big basic side chain, whereas Gly is a nonpolar amino acid
with the least side chain volume. More importantly, occur-
rence of Gly residue would destabilize an  -helix structure in
the second Ig- like domain because it has more conforma-
tional flexibility than other amino acids [37]. Taking together
the changes in the side chain volume, hydropathy, and  -
helix stability due to Gly substitution for Arg at codon 201
may alter the conformation of the DCC protein, resulting in
the activity of the codon 201Gly type DCC protein much
weaker than that of the wild type codon 201Arg DCC protein.
This may diminish the tumor-suppressor function of DCC
and contribute to the progression or dissemination of the
tumors. Because codon 201Arg /Gly type is not shown to be
related to the progression of the colorectal carcinomas
[25,26] and the dissemination of neuroblastoma in this
study, it is likely that the presence of one codon 201Arg allele
is enough to produce functional DCC protein. Alternatively,
the codon 201Arg allele is selectively transcribed. Loss of
DCC expression and/or function activity may occur only
when both of codon 201Arg alleles are deleted, for example,
in codon 201Gly type tumors.
In summary, our study showed that the CGA (Arg) to
GGA (Gly) substitution at codon 201 in both alleles is more
frequent in disseminated neuroblastomas, suggesting that
the polymorphism change from codon 201Arg type to codon
201Gly type might be involved in tumor dissemination. The
high frequency of codon 201Gly type of the DCC gene in
disseminated neuroblastomas also suggests that this varia-
tion might be a helpful genetic marker for these tumors.
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